Predicting Complete Response to Neoadjuvant Chemotherapy in Muscle-Invasive Bladder CancerHiroko Miyagi, Paul L. Crispen, Wayne Brisbane et al.|Cancers|2022Cited by 27
Correlation of Ki-67 Proliferative Antigen Expression and Tumor Response to Induction Chemotherapy Containing Cell Cycle-Specific Agents in Head and Neck Squamous Cell CarcinomaJonathan Alexander Chatzkel, Douglas R. Adkins, Barry A. Siegel et al.|Head and Neck Pathology|2016Cited by 11
Overall responses with coordinated pembrolizumab and high dose IL-2 (5-in-a-row schedule) for therapy of metastatic clear cell renal cancer: A single center, single arm trial.Jonathan Alexander Chatzkel, Mayer Fishman, Jennifer Swank et al.|Journal of Clinical Oncology|2019Cited by 8
Gender Disparities in the Clinical Trials and Real-World Utilization of Systemic Therapy in the Management of Urothelial CarcinomaHiroko Miyagi, Padraic O’Malley, Jonathan Alexander Chatzkel et al.|JU Open Plus|2023Cited by 4
A phase Ib/II study (IMMCO-1) of atezolizumab plus tivozanib in castrate-resistant prostate cancer and certain other immunologically cold tumors.Jonathan Alexander Chatzkel, Brian Hemendra Ramnaraign, Ji‐Hyun Lee et al.|Journal of Clinical Oncology|2023Cited by 0